2021-12-01 | Results from Orviglance comparison study to gadolinium presented at RSNA 2021 PDF PDF Report Presentation Webcast
Regulatory 2021-11-30 | Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB PDF Report Presentation Webcast
2021-10-19 | Ascelia Pharma’s Food Effect Study with Orviglance successfully completed PDF Report Presentation Webcast
Regulatory 2021-09-21 | Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF® PDF Report Presentation Webcast
Regulatory 2021-08-18 | Covid-19 extends recruitment period of SPARKLE study PDF Report Presentation Webcast
2021-08-13 | Abstract for Orviglance comparison study to gadolinium accepted at the world’s largest radiology conference RSNA PDF Report Presentation Webcast
2021-08-10 | Ascelia Pharma receives conditional FDA acceptance for brand name Orviglance PDF Report Presentation Webcast
Regulatory 2021-04-15 | Ascelia Pharma AB publishes prospectus regarding admission to trading of newly issued shares on Nasdaq Stockholm PDF Report Presentation Webcast
Regulatory 2021-04-09 | Issue and repurchase of series C shares for share saving program PDF Report Presentation Webcast
2021-03-02 | Ascelia Pharma opens US office in preparation for Mangoral launch PDF Report Presentation Webcast
2021-01-12 | Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy PDF Report Presentation Webcast
Regulatory 2020-12-15 | Ascelia Pharma gets US patent for second generation Mangoral PDF Report Presentation Webcast
Regulatory 2020-12-02 | New study shows Mangoral’s lesion visualization as effective as gadolinium contrast agent PDF Report Presentation Webcast
2020-11-03 | EMA confirms Mangoral eligible for the centralized regulatory procedure in the EU PDF Report Presentation Webcast
Regulatory 2020-10-21 | Upgraded estimate of addressable market for Mangoral to $500-600 million annually PDF Report Presentation Webcast
2020-05-26 | Vator Securities: Ascelia Pharma: A delay. Fundamentals for Mangoral remain unchanged. PDF Report Presentation Webcast
Regulatory 2020-05-20 | Updated SPARKLE timelines due to Covid-19 impact PDF Report Presentation Webcast
